Role of different inflammatory and tumor biomarkers in the development of ulcerative colitis-associated carcinogenesis

Inflammatory Bowel Diseases

Volumn 17, Issue 3, 2011, Pages 696-710

  Talero, E ^a   Sanchez Fidalgo S ^a   Villegas, I ^a   De La Lastra, C Alarcón ^a   Illanes, M ^b   Motilva, V ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

adrenomedullin; chronic inflammation; colon carcinogenesis; cytokines; iNOS

Indexed keywords

ADRENOMEDULLIN; BETA CATENIN; BIOLOGICAL MARKER; CYCLINE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; PROSTAGLANDIN E SYNTHASE 1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ULCERATIVE COLITIS; WESTERN BLOTTING;

ADENOCARCINOMA; ADRENOMEDULLIN; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYTOKINES; DEXTRAN SULFATE; FEMALE; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79551526537     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21420     Document Type: Article

References (78)

1. Hardy RG, Meltzer SJ, Jankowski JA,. ABC of colorectal cancer. Molecular basis for risk factors. BMJ. 2000; 321: 886-889.
2. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459. (Pubitemid 38182302)
3. Xie J, Itzkowitz SH,. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 378-389. (Pubitemid 351320846)
4. Rubin DT, Parekh N,. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Opt Gastroenterol. 2006; 9: 211-220. (Pubitemid 43853436)
5. Okayasu I, Ohkusa T, Kajiura K, et al. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut. 1996; 39: 87-92. (Pubitemid 26239112)
6. Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 2003; 94: 965-973. (Pubitemid 37508979)
7. Suzuki R, Kohno H, Sugie S, et al. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci. 2004; 95: 721-727. (Pubitemid 39335091)
8. Tamaru T, Kobayashi H, Kishimoto S, et al. Histochemical study of colonic cancer in experimental colitis of rats. Dig Dis Sci. 1993; 38: 529-537. (Pubitemid 23087130)
9. Yamada M, Ohkusa T, Okayasu I,. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulfate sodium. Gut. 1992; 33: 1521-1527.
10. Clapper ML, Cooper HS, Chang WC,. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin. 2007; 28: 1450-1459. (Pubitemid 47366692)
11. Jin T, George Fantus I, Sun J,. Wnt and beyond Wnt: multiple mechanisms control the transcriptional property of beta-catenin. Cell Signal. 2008; 20: 1697-1704.
12. Shinozaki M, Watanabe T, Kubota Y, et al. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis Colon Rectum. 2000; 43: S34-S39.
13. Vetuschi A, Latella G, Sferra R, et al. Increased proliferation and apoptosis of colonic epithelial cells in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci. 2002; 47: 1447-1457. (Pubitemid 34753919)
14. Burstein E, Fearon ER,. Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest. 2008; 118: 464-467. (Pubitemid 351206535)
15. Agoff SN, Brentnall TA, Crispin DA, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000; 157: 737-745. (Pubitemid 32109366)
16. van der Woude CJ, Kleibeuker JH, Jansen PL, et al. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis. 2004; 9: 123-130. (Pubitemid 38987589)
17. Wang D, Dubois RN,. Prostaglandins and cancer. Gut. 2006; 55: 115-122. (Pubitemid 41820645)
18. Kanwar JR, Kanwar RK, Burrow H, et al. Recent advances on the roles of NO in cancer and chronic inflammatory disorders. Curr Med Chem. 2009; 16: 2373-2394.
19. Talero E, Sánchez-Fidalgo S, de la Lastra CA, et al. Acute and chronic responses associated with adrenomedullin administration in experimental colitis. Peptides. 2008; 29: 2001-2012.
20. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut. 2006; 55: 824-832. (Pubitemid 43764553)
21. Ashizuka S, Ishikawa N, Kato J, et al. Effect of adrenomedullin administration on acetic acid-induced colitis in rats. Peptides. 2005; 26: 2610-2615. (Pubitemid 41676739)
22. Gonzalez-Rey E, Delgado M,. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci. 2007; 28: 482-491. (Pubitemid 47368698)
23. Cuttitta F, Pio R, Garayoa M, et al. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis. Microsc Res Tech. 2002; 57: 110-119. (Pubitemid 34438617)
24. Zudaire E, Martinez A, Cuttitta F,. Adrenomedullin and cancer. Regul Pept. 2003; 112: 175-183. (Pubitemid 36351615)
25. Oehler MK, Hague S, Rees MC, et al. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene. 2002; 21: 2815-2821. (Pubitemid 34499378)
26. Nikitenko LL, Fox SB, Kehoe S, et al. Adrenomedullin and tumour angiogenesis. Br J Cancer. 2006; 94: 1-7. (Pubitemid 43088532)
27. Carrier JC, Aghdassi E, Jeejeebhoy K, et al. Exacerbation of dextran sulfate sodium-induced colitis by dietary iron supplementation: role of NF-kappaB. Int J Colorectal Dis. 2006; 21: 381-387. (Pubitemid 43880544)
28. Seril DN, Liao J, Yang CS, et al. Systemic iron supplementation replenishes iron stores without enhancing colon carcinogenesis in murine models of ulcerative colitis: comparison with iron-enriched diet. Dig Dis Sci. 2005; 50: 696-707. (Pubitemid 40558464)
29. Erichsen K, Milde AM, Arslan G, et al. Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm Bowel Dis. 2005; 11: 744-748 (Pubitemid 41271179)
30. Yeo M, Kim DK, Park HJ, et al. Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics. 2006; 6: 1158-1165.
31. Gommeaux J, Cano C, Garcia S, et al. Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1. Mol Cell Biol. 2007; 27: 2215-2228. (Pubitemid 46418477)
32. Bird RP, Good CK,. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett. 2000; 15: 395-402. (Pubitemid 30138150)
33. Okayasu I, Yamada M, Mikami T, et al. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol. 2002; 17: 1078-1083. (Pubitemid 35013962)
34. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983; 14: 931-968.
35. Osawa E, Nakajima A, Fujisawa T, et al. Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer. 2006; 118: 2232-2236.
36. Sánchez-Fidalgo S, Martín-Lacave I, Illanes M, et al. Angiogenesis, cell proliferation and apoptosis in gastric ulcer healing. Effect of a selective cox-2 inhibitor. Eur J Pharmacol. 2004; 505: 187-194. (Pubitemid 39535691)
37. Oehler MK, Fischer DC, Orlowska-Volk M, et al. Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer. 2003; 89: 1927-1933. (Pubitemid 37533272)
38. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976; 72: 248-254.
39. Gupta AK, Schoen RE,. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans? Curr Opin Gastroenterol. 2009; 25: 59-65.
40. Itzkowitz SH, Yio X,. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004; 287: G7-17. (Pubitemid 38802113)
41. Motilva V, Talero E, Calvo JR, et al. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities. Curr Pharm Des. 2008; 14: 71-95. (Pubitemid 351266986)
42. Orlando FA, Tan D, Baltodano JD, et al. Aberrant crypt foci as precursors in colorectal cancer progression. J Surg Oncol. 2008; 98: 207-213.
43. Whiteley LO, Hudson L Jr, Pretlow TP,. Aberrant crypt foci in the colonic mucosa of rats treated with a genotoxic and nongenotoxic colon carcinogen. Toxicol Pathol. 1996; 24: 681-689. (Pubitemid 27029912)
44. Kohno H, Suzuki R, Sugie S, et al. Beta-catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 2005; 96: 69-76. (Pubitemid 40425381)
45. Mikami T, Mitomi H, Hara A, et al. Decreased expression of CD44, alpha-catenin, and deleted colon carcinoma and altered expression of beta-catenin in ulcerative colitis-associated dysplasia and carcinoma, as compared with sporadic colon neoplasms. Cancer. 2000; 89: 733-740. (Pubitemid 30658570)
46. Mees ST, Mennigen R, Spieker T, et al. Expression of tight and adherens junction proteins in ulcerative colitis associated colorectal carcinoma: upregulation of claudin-1, claudin-3, claudin-4, and beta-catenin. Int J Colorectal Dis. 2009; 24: 361-368.
47. Hasselblatt P, Gresh L, Kudo H, et al. The role of the transcription factor AP-1 in colitis-associated and beta-catenin-dependent intestinal tumorigenesis in mice. Oncogene. 2008; 27: 6102-6109.
48. Yoshimi K, Tanaka T, Takizawa A, et al. Enhanced colitis-associated colon carcinogenesis in a novel Apc mutant rat. Cancer Sci. 2009; 100: 2022-2027.
49. Weber CR, Nalle SC, Tretiakova M, et al. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008; 88: 1110-1120.
50. Essers J, Theil AF, Baldeyron C, et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol. 2005; 25: 9350-9359. (Pubitemid 41507836)
51. Liao J, Seril DN, Yang AL, et al. Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. Carcinogenesis. 2007; 28: 446-454. (Pubitemid 46321862)
52. Romero M, Artigiani R, Costa H, et al. Evaluation of the immunoexpression of COX-1, COX-2 and p53 in Crohn's disease. Arq Gastroenterol. 2008; 45: 295-300.
53. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118: 560-570. (Pubitemid 351206546)
54. Rose-John S, Mitsuyama K, Matsumoto S, et al. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Curr Pharm Des. 2009; 15: 2095-2103.
55. Hanada T, Kobayashi T, Chinen T, et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med. 2006; 203: 1391-1397. (Pubitemid 43877600)
56. Popivanova BK, Kostadinova FI, Furuichi K, et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res. 2009; 69: 7884-7892.
57. Kraus S, Arber N,. Inflammation and colorectal cancer. Curr Opin Pharmacol. 2009; 9: 405-410.
58. Zamuner SR, Bak AW, Devchand PR, et al. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol. 2005; 167: 1293-1300. (Pubitemid 41541415)
59. Chulada PC, Thompson MB, Mahler JF, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 2000; 60: 4705-4708.
60. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996; 87: 803-809. (Pubitemid 26404280)
61. Mosca M, Polentarutti N, Mangano G, et al. Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. J Leukoc Biol. 2007; 82: 320-326. (Pubitemid 47230643)
62. van Rees BP, Sivula A, Thorén S, et al. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer. 2003; 107: 551-556. (Pubitemid 37296114)
63. Kamei D, Murakami M, Nakatani Y, et al. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem. 2003; 278: 19396-19405. (Pubitemid 36799335)
64. Tatsuguchi A, Seo T, Shinji S, et al. Clinical significance of prostaglandin e synthase expression in colorectal cancer. J Nippon Med Sch. 2006; 73: 38-41.
65. Nakanishi M, Montrose DC, Clark P, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008; 68: 3251-3259.
66. Ahn B, Ohshima H,. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res. 2001; 61: 8357-8360. (Pubitemid 33131104)
67. Scott DJ, Hull MA, Cartwright EJ, et al. Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology. 2001; 121: 889-899. (Pubitemid 32959398)
68. Seril DN, Liao J, Yang GY,. Colorectal carcinoma development in inducible nitric oxide synthase-deficient mice with dextran sulfate sodium-induced ulcerative colitis. Mol Carcinog. 2007; 46: 341-353. (Pubitemid 46744454)
69. Mukawa K, Fujii S, Tominaga K, et al. Inhibitory effects of the cyclooxygenase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-deficient mice treated with dextran sulfate sodium. Oncol Rep. 2008; 19: 393-399. (Pubitemid 351176099)
70. Kohno H, Takahashi M, Yasui Y, et al. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male Apc(Min/+) mice. Int J Cancer. 2007; 121: 506-513. (Pubitemid 46986482)
71. García MA, Martín-Santamaría S, de Pascual-Teresa B, et al. Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets. 2006; 10: 303-317.
72. Delgado M, Ganea D,. Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents. Brain Behav Immun. 2008; 22: 1146-1151.
73. Liu J, Bützow R, Hydén-Granskog C, et al. Expression of adrenomedullin in human ovaries, ovarian sex cord-stromal tumors and cultured granulosa-luteal cells. Gynecol Endocrinol. 2009; 25: 96-103.
74. Martínez A, Vos M, Guédez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst. 2002; 94: 1226-1237. (Pubitemid 34993873)
75. Nakamura M, Han B, Nunobiki O, et al. Adrenomedullin: a tumor progression factor via angiogenic control. Curr Cancer Drug Targets. 2006; 6: 635-643. (Pubitemid 44691005)
76. Abasolo I, Montuenga LM, Calvo A,. Adrenomedullin prevents apoptosis in prostate cancer cells. Regul Pept. 2006; 133: 115-122. (Pubitemid 41820344)
77. Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer. 2007; 121: 21-32. (Pubitemid 46759489)
78. Kaafarani I, Fernandez-Sauze S, Berenguer C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J. 2009; 23: 3424-3435.